The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Infectious Disease Therapeutics Market Expected To Change From 2026 To 2030?
The infectious disease therapeutics market size has observed substantial growth in recent years. This market is set to expand from $150.6 billion in 2025 to $160.84 billion in 2026, advancing at a compound annual growth rate (CAGR) of 6.8%. The expansion during the historic period can be attributed to the significant global burden of infectious diseases, the widespread use of antibiotics and antivirals, government immunization programs, an increase in pharmaceutical manufacturing capacity, and enhanced funding for infectious disease research.
The infectious disease therapeutics market size is projected to experience robust expansion over the coming years. It is expected to reach $200.87 billion by 2030, progressing at a compound annual growth rate (CAGR) of 5.7%. This growth during the forecast period can be attributed to escalating antimicrobial resistance rates, a greater frequency of infectious disease outbreaks, the expansion of global vaccination coverage, an increasing demand for novel antiviral therapies, and stronger public health preparedness initiatives. Furthermore, major trends in the forecast period include a rising focus on antimicrobial resistance management, the increasing development of broad-spectrum therapeutics, a growing adoption of combination drug therapies, the expansion of rapid-response therapeutics for outbreaks, and increased investment in vaccine research and stockpiling.
Access Your Free Sample Report For In-Depth Market Analysis:
What Factors Are Contributing To The Growth Of The Infectious Disease Therapeutics Market?
The increasing incidence of infectious diseases is anticipated to boost the expansion of the infectious disease therapeutics market in the future. These illnesses are caused by pathogenic microorganisms such as bacteria, viruses, fungi, parasites, or prions. The surge in infectious diseases is attributable to various critical elements like climate change and environmental disruption, antimicrobial resistance, compromised immune systems, heightened interactions with animals, and ecological disturbances. Therapeutics for infectious diseases are crucial for treating infections, diminishing morbidity and mortality, and managing the dissemination of communicable illnesses within communities and across populations. For instance, in October 2023, the National Health Service (NHS) England, a UK-based government department, reported that hospitals recorded 147,285 admissions with a primary diagnosis of urinary tract infection (UTI) in 2022/23. Patients aged over 65 represented 56% of these cases, amounting to 82,392 admissions. The 80–84 age group had the highest number of admissions, with 17,280 cases. Consequently, the growing occurrence of infectious diseases propels the infectious disease therapeutics market.
How Is The Infectious Disease Therapeutics Market Broken Down By Segment Categories?
The infectious disease therapeutics market covered in this report is segmented –
1) By Type: Drugs, Vaccines
2) By Disease: Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases
3) By End-User: Hospitals And Clinics, Retail Pharmacies, Research Organizations, Other End Users
Subsegments:
1) By Drugs: Antibiotics, Antivirals, Antifungals, Antiparasitics, Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)
2) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Mrna Vaccines, Dna Vaccines, Toxoid Vaccines
What Trends Are Shaping The Future Of The Infectious Disease Therapeutics Market?
Major companies operating within the infectious disease therapeutics market are strategically incorporating multispecific antibody platforms, such as the multispecific therapeutic antibody reactor (MSTAR), to improve efficacy, extend protection, and strengthen their responsiveness to emerging viral threats. The multispecific therapeutic antibody reactor (MSTAR) is an advanced multispecific antibody technology that merges several independent binding regions into a single therapeutic molecule, facilitating capabilities such as broad viral neutralization, simultaneous targeting of multiple epitopes, and rapid adaptation to new variants. For instance, in September 2023, ModeX Therapeutics Inc, a US-based clinical stage biopharmaceutical company, secured a contract from the Biomedical Advanced Research and Development Authority to advance its multispecific antibody candidates designed for the treatment and prevention of viral infectious diseases including COVID 19 and influenza, which feature broad activity against circulating viral strains, potential compatibility with gene based delivery using mRNA or DNA vectors, and a multi binding site architecture. This multispecific antibody strategy enhances therapeutic outcomes by shortening development timelines, expanding protective coverage, and reducing the complexity associated with combination biologic treatments.
Which Players Are Present In The Infectious Disease Therapeutics Market Space?
Major companies operating in the infectious disease therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, AstraZeneca, Novartis International AG, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceuticals, Moderna Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioCryst Pharmaceuticals Inc.
Get The Full Infectious Disease Therapeutics Market Report:
Which Region Has The Greatest Market Share In The Infectious Disease Therapeutics Market?
North America was the largest region in the infectious disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Infectious Disease Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Infectious Disease Therapeutics Market 2026, By The Business Research Company
Anti Infective Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market
Anti Infective Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report
Therapeutic Bcg Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model